Trials / Unknown
UnknownNCT03553004
Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- University of Kansas Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA approved and commercially available for the treatment of ovarian cancer. Its use in this study is investigational.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niraparib Treatment | Niraparib treatment by mouth (oral) |
Timeline
- Start date
- 2019-01-22
- Primary completion
- 2023-04-25
- Completion
- 2025-02-01
- First posted
- 2018-06-12
- Last updated
- 2023-05-19
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03553004. Inclusion in this directory is not an endorsement.